-
- Investment Summit
Registration & networkingRegistration
-
- Investment Summit
)
-
- Investment Summit
Bringing together investors across the funding spectrum (from seed-stage VCs to growth investors) to share what drives decision making in today’s market
)
)
)
-
- Investment Summit
The gaps biotech startups face beyond just funding Followed by investor reflections – how they can better support startups beyond capital
)
)
)
)
)
-
- Investment Summit
A candid conversation between a biotech founder and their early investor exploring the startup journey
)
)
-
- Investment Summit
Refreshment & networking break1-2-1 Meetings
-
- Investment Summit
Pioneering investment model: Explore how Europe’s first dedicated fund for children's health was originally conceived, addressing a long-standing funding gap in innovation for children’s medicines, te ...
)
-
- Investment Summit
A rapid-fire panel / multi-perspective session on high-growth areas in biotech.
)
)
)
-
- Investment Summit
Wrap up from senior VC – covering the landscape of what’s next and where biotech investment will grow for the next 5 years
-
- Investment Summit
- Women in Advanced Therapies Congress
Investment Summit & Women In Advanced Therapies LunchLunch break and networking -
- Investment Summit
- Women in Advanced Therapies Congress
Investment Summit & Women In Advanced Therapies LunchLunch break and networking
-
- Women in Advanced Therapies Congress
Welcome address
)
-
- Women in Advanced Therapies Congress
Explore the complex mix of visible and invisible barriers that shape entry into the industry. Address systemic challenges and how we can create a truly inclusive workforce
)
)
)
)
-
- Women in Advanced Therapies Congress
Networking break1-2-1 Meetings
-
- Women in Advanced Therapies Congress
-
- Women in Advanced Therapies Congress
-
- Women in Advanced Therapies Congress
-
- Women in Advanced Therapies Congress
-
- Women in Advanced Therapies Congress
-
- Women in Advanced Therapies Congress
-
- Women in Advanced Therapies Congress
-
- Women in Advanced Therapies Congress
-
- Women in Advanced Therapies Congress
-
- Women in Advanced Therapies Congress
)
)
)
)
)
)
)
-
- Women in Advanced Therapies Congress
Refreshment & networking break1-2-1 Meetings
-
- Women in Advanced Therapies Congress
Following on from the earlier roundtables, the moderator from each table will share the key points from the discussion. Enabling audience members to receive insights across all topics and encouraging further discussion post-event.
-
- Women in Advanced Therapies Congress
-
Building resilience and strategy crucial for long term success
-
Navigating uncertainty and leading with confidence
-
Owning your leadership style and being a successful leader
-
- Women in Advanced Therapies Congress
Closing address
-
- Networking
Join us for an unforgettable evening overlooking the marina at the iconic Hotel Arts Barcelona. Connect with fellow attendees – expect great impressive views, great conversation, and a few surprises a ...
-
- Networking
Begin your day with an energising run along Barcelona’s waterfront. Join fellow delegates for a casual 5k starting from the Hotel Arts lobby, blending light exercise, fresh sea air, and plenty of info ...
-
- Networking
-
- Workshop
Scaling for ATMP commercialisation
-
Natacha Agabalyan
Associate Lead Scientist, Technology and Process Innovation - Cell and Gene Therapy Catapult -
Rhys Macown
Lead Scientist - Cell and Gene Therapy Catapult -
Jenny Stjernberg
Sr Director of Global Sales & Business Development, Cell & Gene Therapy Technologies - Fresenius Kabi -
Damian Marshall
VP Analytical Development - Resolution Therapeutics -
Terri Gaskell
CTO - Rinri Therapeutics -
Walid Fahme
COO - Autolomous
)
)
)
)
-
- Plenary
)
-
- Plenary
This session will explore the current state of the CGT industry, with a focus on Europe’s evolving role amid global shifts. In a climate where research ecosystems face mounting uncertainty — particularly following moves in the U.S. to scale back federal support for scientific innovation, Europe must sharpen its competitiveness to secure its leadership in advanced therapies. We will examine emerging trends, key market dynamics, and the urgent need for Europe to overcome challenges around scalability, affordability, and patient access. The discussion will highlight how external pressures are reshaping Europe’s strategic priorities — and what actions are needed now to turn today’s challenges into tomorrow’s leadership in CGT.
)
)
)
)
-
- Plenary
Deep dive into the regulatory framework that governs CGT across major rejoins, focusing on recent updates, new legislation and how companies can navigate the changing landscape.
)
)
)
-
- Networking
Coffee and networking break
-
- Workshop
Highlight how the UK is strengthening its ATMP ecosystem through coordinated infrastructure, regulatory agility, and health system integration — with a forward-looking, opportunity-driven lens.
-
- R&D, clinical innovation & translation
- Cutting edge developments in CRISPR, gene editing and cell engineering
- The next wave of in vivo and ex vivo gene therapies
- What breakthroughs are expected to reshape the industry?
-
- Manufacturing, scale up & commercial strategy
-
As the pressure mounts to deliver advanced therapies faster, cheaper, and closer to the patient, decentralised manufacturing is stepping into the spotlight. But does breaking away from centralised models really deliver on cost?
-
This panel dives into the economic realities behind the decentralisation trend. Are localised manufacturing hubs the answer to cutting costs, or do they introduce new layers of complexity and hidden spend? From infrastructure investments to regulatory headaches, we’ll separate financial fact from fiction and explore whether decentralisation is a bold leap forward or an expensive detour.
)
)
)
)
)
)
)
)
)
)
-
- Workshop
Showcase how Nordic countries are combining national strengths in biomanufacturing, data infrastructure, and public-private partnerships to build a regional ATMP hub.
-
- R&D, clinical innovation & translation
-
- Manufacturing, scale up & commercial strategy
)
)
)
)
-
- Workshop
Invite only
Model – leave your company affiliation at the door. This is a non-competitive, bias-free space – if you want to wax lyrical about your capabilities or tech, do it in the hallway (or in the ATE agenda!). This is a open-collaborative space and we want participants to have an equal footing and contribution to challenges and eventual solutions.
-
- R&D, clinical innovation & translation
-
- Manufacturing, scale up & commercial strategy
)
-
- R&D, clinical innovation & translation
-
Why characterisation and analytics remain a major hurdle.
-
Collaborative approaches to tackling technical challenges
-
Best practices and emerging solutions.
-
- Manufacturing, scale up & commercial strategy
- Balancing technical and financial realities in manufacturing
- When to invest in infrastructure vs outsourcing
- The role of automation in optimising CMC process
)
)
)
)
-
- Workshop
Lunch provided
)
)
-
- Networking
Lunch & networking break1-2-1 meetings
-
- R&D, clinical innovation & translation
-
How startups secure investment before reaching human trials
-
strategic and tactical guidance on how to secure the right funding at the right time, from seed rounds through Series A
-
Investor insights into due diligence, risk mitigation and valuation and what good really looks like
-
- Manufacturing, scale up & commercial strategy
-
Transitioning from academic proof of concept to first-in-human
-
Why biotech teams must integrate CMC, regulatory and pharmacology early
-
Avoiding pitfalls of overselling and overpromising
)
)
)
)
)
)
-
- Workshop
-
- R&D, clinical innovation & translation
Current key barriers impeding progress toward first-in-human trials in cell therapies, as well as highlights on strategies - from discovery through CMC development - to overcome these challenges with ... -
- Manufacturing, scale up & commercial strategy
)
)
)
)
-
- R&D, clinical innovation & translation
-
- Manufacturing, scale up & commercial strategy
Cell therapies through their curative potential offer life-changing treatment options to patients with no other recourse. In a few short years, they have achieved unprecedented success as evidenced by ...
)
-
- R&D, clinical innovation & translation
-
- Manufacturing, scale up & commercial strategy
)
)
-
- R&D, clinical innovation & translation
-
- Manufacturing, scale up & commercial strategy
)
)
-
- Networking
Coffee break & networking1-2-1 Meetings
-
- Roundtable
IP and exclusivity strategies for navigating CGT innovations from conception to commercialization
-
- Roundtable
From Bench to Bedside Successfully: ATMPs commercial strategy long before Phase III -
- Roundtable
Gene therapy communication strategy: Bridging development, approval and stakeholder engagement beyond KOLs -
- Roundtable
Digital Infrastructure & Data Harmonisation: Enablers for CGT Access & Scale -
- Roundtable
Funding strategies for early-stage cell and gene therapy companies -
- Roundtable
Academic Innovation vs Industry Expectations: How to translate your Preclinical Data -
- Roundtable
Building the right team – who should be involved at each development stage? -
- Roundtable
Overcoming the barriers to scale-up in cell therapy manufacturing -
- Roundtable
Promises and challenges of current in vivo CAR-T therapy approaches -
- Workshop
Explore Spain’s growing potential as a strategic ATMP manufacturing and clinical trial hub within the EU.
)
)
)
)
)
-
- Networking
Networking Happy Hour
-
- Workshop
Adeno-associated virus (AAV) remains the predominant viral vector in gene therapy, with recent funding trends favoring de-risked programs supported by strong clinical data and commercial viability.
)
)
-
- Plenary
Welcome remarks day 2
-
- Workshop
Invite only
Model – leave your company affiliation at the door. This is a non-competitive, bias-free space – if you want to wax lyrical about your capabilities or tech, do it in the hallway (or in the ATE agenda!). This is a open-collaborative space and we want participants to have an equal footing and contribution to challenges and eventual solutions.
Session overview:
- Welcome and framing from moderators/advisory committee, framing key automation challenges (labor dependency, reproducibility, tech transfer)
- Introductions (Name, org, and interest in automation)
- Facilitated roundtable with 2-3 breakout themes to guide the discussion
-
- Plenary
Join us for an exciting session where innovative biotech start-ups pitch their groundbreaking ideas and solutions. Watch as they present to a panel of expert investors, who will provide real-time feedback, insights, and guidance. This is a unique opportunity to explore cutting-edge advancements in the biotech space and gain valuable perspectives from both entrepreneurs and industry leaders.
)
)
)
)
)
)
)
-
- Plenary
Today's CGT startups are facing the toughest fundraising environment in years — and solid science alone isn’t enough. This panel digs into the hard truths: How the market squeeze is reshaping funding dynamics, why traditional playbooks aren't working, and what it takes to stand out when investors are more selective than ever. Real stories. Real setbacks. Real strategies for surviving and scaling in a high-stakes market.
)
)
)
-
- Networking
Networking & coffee break
-
- Workshop
This is a closed-door, outcome-driven discussion bringing together senior leaders to align on immediate, practical steps that can accelerate policy evolution, strengthen the European ATMP ecosystem, and unlock scalable patient access. -
- R&D, clinical innovation & translation
-
- Manufacturing, scale up & commercial strategy
)
)
)
)
-
- R&D, clinical innovation & translation
-
- R&D, clinical innovation & translation
-
- R&D, clinical innovation & translation
-
- Manufacturing, scale up & commercial strategy
)
)
-
- Manufacturing, scale up & commercial strategy
-
- Manufacturing, scale up & commercial strategy
Effective IP strategy for C>s presents unique challenges compared to traditional pharmaceuticals and biologics. To secure robust IP that protects the market and attracts investors, companies need to ...
)
-
- R&D, clinical innovation & translation
-
Best practices for early interactions with EMA, FDA, etc.
-
How proactive regulatory engagement reduces delays and de-risk trials
-
Lessons learned from companies that successfully navigated approval
-
Benjamin Dewees
Senior Vice President of Regulatory Affairs - Artiva Biotherapeutics -
Aneta Tyszkiewicz
Director Digital and Data - European Federation of Pharmaceutical Industries and Associations -
Mariana Gomez
Senior Regulatory Consultant - Zwiers Regulatory Consultancy, a ProductLife Group Company -
Anna Koptina
Head of Regulatory Affairs - Elicera Therapeutics
-
- Manufacturing, scale up & commercial strategy
-
Explore strategies for securing reimbursement and market access for cell and gene therapies, focusing on pricing, HTAs, and policy advocacy to ensure patient access.
)
)
)
)
)
-
- Workshop
Lunch provided
- From automation to human-centric, intelligent manufacturing
- Integrating AI, machine learning, and digital systems for adaptive workflows
- Empowering technicians with smart, collaborative technologies
-
Alexander Seyf
CEO & Cofounder - Autolomous -
Edwin Bremer
Professor - Groningen University Medical Center -
Steven Feldman
Site Head and Scientific Director - Laboratory of Cell and Gene Medicine (Stanford GMP Facility) -
Mounzer Agha
Physician - Hillman Cancer Center, University of Pittsburgh -
Arnaud Deladeriere
President & Principal Consultant - CGT Consulting -
Edwin Beale
CBO - Cellipont
)
)
)
)
)
)
)
-
- Networking
Lunch break1-2-1 meetings
-
- Plenary
-
- Plenary
AI is everywhere, but in CGT, real deployment remains limited. This session goes beyond the buzz to explore the tangible opportunities, early wins, and critical barriers to broader adoption. We’ll loo ...
)
)
-
- Plenary
As we wrap up two days of deep discussions on the current state of the European CGT landscape, this final panel will chart the path ahead. Which steps must Europe take to remain competitive and lead the way in the next 5–10 years? Each panellist will share their key takeaways from the last two days, reflecting on the insights, challenges, and opportunities discussed.
)